Tag Archives: Investment

Into the Extrapolation Machine: How We Joined the Elite 58%

By Les Funtleyder. The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. With respect to investing, uncertainly caused by media/pundit noise often depresses valuations in [...]
Posted in Guest Blog, Op-Ed, healthcare | Also tagged , , , , , , , , , | Leave a comment

Past Performance Is No Indication Of Future Results

Sponsored Guest blog post by Patrick Homer, Life Science Practice Principal, SAS. The lingo that accompanies every financial investment prospectus has never been more apt in our post meltdown economy. Yet when it comes down to directing the billion dollar investments in sales and marketing spends, the pharma industry has been firmly entrenched in this belief. [...]
Posted in Guest Blog, Strategy | Also tagged , , , , , , | Leave a comment

Upcoming Webcast: Data Driven Laboratory Asset Management Programs

Unlock unknown capital and drive efficiency while improving quality and scientist experience Wednesday, June 17, 2009 at 10 AM EST With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify [...]
Posted in Webcast | Also tagged , , , , , , | Leave a comment